FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156996711> ?p ?o ?g. }

• W3156996711 endingPage "1162" @default.
• W3156996711 startingPage "1156" @default.
• W3156996711 abstract "The combination of cyclophosphamide and prednisolone is effective for the treatment of severe lupus nephritis but has serious adverse effects. Whether mycophenolate mofetil can be substituted for cyclophosphamide is not known.In 42 patients with diffuse proliferative lupus nephritis we compared the efficacy and side effects of a regimen of prednisolone and mycophenolate mofetil given for 12 months with those of a regimen of prednisolone and cyclophosphamide given for 6 months, followed by prednisolone and azathioprine for 6 months. Complete remission was defined as a value for urinary protein excretion that was less than 0.3 g per 24 hours, with normal urinary sediment, a normal serum albumin concentration, and values for serum creatinine and creatinine clearance that were no more than 15 percent above the base-line values. Partial remission was defined as a value for urinary protein excretion that was between 0.3 and 2.9 g per 24 hours, with a serum albumin concentration of at least 30 g per liter.Eighty-one percent of the 21 patients treated with mycophenolate mofetil and prednisolone (group 1) had a complete remission, and 14 percent had a partial remission, as compared with 76 percent and 14 percent, respectively, of the 21 patients treated with cyclophosphamide and prednisolone followed by azathioprine and prednisolone (group 2). The improvements in the degree of proteinuria and the serum albumin and creatinine concentrations were similar in the two groups. One patient in each group discontinued treatment because of side effects. Infections were noted in 19 percent of the patients in group 1 and in 33 percent of those in group 2 (P = 0.29). Other adverse effects occurred only in group 2; they included amenorrhea (in 23 percent of the patients), hair loss (19 percent), leukopenia (10 percent), and death (10 percent). The rates of relapse were 15 percent and 11 percent, respectively.For the treatment of diffuse proliferative lupus nephritis, the combination of mycophenolate mofetil and prednisolone is as effective as a regimen of cyclophosphamide and prednisolone followed by azathioprine and prednisolone but is less toxic." @default.
• W3156996711 created "2021-04-26" @default.
• W3156996711 creator A5004488408 @default.
• W3156996711 creator A5008203320 @default.
• W3156996711 creator A5047746252 @default.
• W3156996711 creator A5049434567 @default.
• W3156996711 creator A5051698730 @default.
• W3156996711 creator A5052193047 @default.
• W3156996711 creator A5055917280 @default.
• W3156996711 creator A5058280153 @default.
• W3156996711 creator A5076890201 @default.
• W3156996711 creator A5083880078 @default.
• W3156996711 creator A5085813716 @default.
• W3156996711 date "2000-10-19" @default.
• W3156996711 modified "2023-10-17" @default.
• W3156996711 title "Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis" @default.
• W3156996711 cites W1971058219 @default.
• W3156996711 cites W1995752760 @default.
• W3156996711 cites W2029308711 @default.
• W3156996711 cites W2030868704 @default.
• W3156996711 cites W2088434842 @default.
• W3156996711 cites W2135881786 @default.
• W3156996711 cites W2145255000 @default.
• W3156996711 cites W2146203649 @default.
• W3156996711 cites W2314483451 @default.
• W3156996711 cites W2325870812 @default.
• W3156996711 cites W2336236972 @default.
• W3156996711 cites W2336696641 @default.
• W3156996711 cites W4230996310 @default.
• W3156996711 doi "https://doi.org/10.1056/nejm200010193431604" @default.
• W3156996711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11036121" @default.
• W3156996711 hasPublicationYear "2000" @default.
• W3156996711 type Work @default.
• W3156996711 sameAs 3156996711 @default.
• W3156996711 citedByCount "858" @default.
• W3156996711 countsByYear W31569967112012 @default.
• W3156996711 countsByYear W31569967112013 @default.
• W3156996711 countsByYear W31569967112014 @default.
• W3156996711 countsByYear W31569967112015 @default.
• W3156996711 countsByYear W31569967112016 @default.
• W3156996711 countsByYear W31569967112017 @default.
• W3156996711 countsByYear W31569967112018 @default.
• W3156996711 countsByYear W31569967112019 @default.
• W3156996711 countsByYear W31569967112020 @default.
• W3156996711 countsByYear W31569967112021 @default.
• W3156996711 countsByYear W31569967112022 @default.
• W3156996711 countsByYear W31569967112023 @default.
• W3156996711 crossrefType "journal-article" @default.
• W3156996711 hasAuthorship W3156996711A5004488408 @default.
• W3156996711 hasAuthorship W3156996711A5008203320 @default.
• W3156996711 hasAuthorship W3156996711A5047746252 @default.
• W3156996711 hasAuthorship W3156996711A5049434567 @default.
• W3156996711 hasAuthorship W3156996711A5051698730 @default.
• W3156996711 hasAuthorship W3156996711A5052193047 @default.
• W3156996711 hasAuthorship W3156996711A5055917280 @default.
• W3156996711 hasAuthorship W3156996711A5058280153 @default.
• W3156996711 hasAuthorship W3156996711A5076890201 @default.
• W3156996711 hasAuthorship W3156996711A5083880078 @default.
• W3156996711 hasAuthorship W3156996711A5085813716 @default.
• W3156996711 hasBestOaLocation W31569967111 @default.
• W3156996711 hasConcept C126322002 @default.
• W3156996711 hasConcept C126894567 @default.
• W3156996711 hasConcept C2776694085 @default.
• W3156996711 hasConcept C2776715498 @default.
• W3156996711 hasConcept C2776755627 @default.
• W3156996711 hasConcept C2776760755 @default.
• W3156996711 hasConcept C2779134260 @default.
• W3156996711 hasConcept C2779561371 @default.
• W3156996711 hasConcept C2779912601 @default.
• W3156996711 hasConcept C2780091579 @default.
• W3156996711 hasConcept C2780306776 @default.
• W3156996711 hasConcept C71924100 @default.
• W3156996711 hasConcept C90924648 @default.
• W3156996711 hasConceptScore W3156996711C126322002 @default.
• W3156996711 hasConceptScore W3156996711C126894567 @default.
• W3156996711 hasConceptScore W3156996711C2776694085 @default.
• W3156996711 hasConceptScore W3156996711C2776715498 @default.
• W3156996711 hasConceptScore W3156996711C2776755627 @default.
• W3156996711 hasConceptScore W3156996711C2776760755 @default.
• W3156996711 hasConceptScore W3156996711C2779134260 @default.
• W3156996711 hasConceptScore W3156996711C2779561371 @default.
• W3156996711 hasConceptScore W3156996711C2779912601 @default.
• W3156996711 hasConceptScore W3156996711C2780091579 @default.
• W3156996711 hasConceptScore W3156996711C2780306776 @default.
• W3156996711 hasConceptScore W3156996711C71924100 @default.
• W3156996711 hasConceptScore W3156996711C90924648 @default.
• W3156996711 hasIssue "16" @default.
• W3156996711 hasLocation W31569967111 @default.
• W3156996711 hasLocation W31569967112 @default.
• W3156996711 hasLocation W31569967113 @default.
• W3156996711 hasOpenAccess W3156996711 @default.
• W3156996711 hasPrimaryLocation W31569967111 @default.
• W3156996711 hasRelatedWork W1886500020 @default.
• W3156996711 hasRelatedWork W1985224808 @default.
• W3156996711 hasRelatedWork W2036318975 @default.
• W3156996711 hasRelatedWork W2065119494 @default.
• W3156996711 hasRelatedWork W2099928036 @default.
• W3156996711 hasRelatedWork W2102103650 @default.

• next